@article{Nrhi_F-2022_80789,
title = {Implementation of corticosteroids in treatment of COVID-19 in the ISARIC WHO Clinical Characterisation Protocol UK: prospective, cohort study},
author = {Närhi, F. and Moonesinghe, S. and Shenki, S. and Drake, T. and Mulholland, R. and Donegan, C. and Dunning, J. and Fairfield, C. and Girvan, M. and Hardwick, H. and Ho, A. and Leeming, G. and Nguyen-Van-Tam, J. and Pius, R. and Russell, C. and Shaw, C. and Spencer, R. and Turtle, L. and Openshaw, P. and Baillie, J. and Harrison, E. and Semple, M. and Docherty, A. and ISARIC4C Investigators},
month = {apr},
year = {2022},
abstract = {Background: Dexamethasone was the first intervention proven to reduce mortality in patients with COVID-19 being treated in hospital. We aimed to evaluate the adoption of corticosteroids in the treatment of COVID-19 in the UK after the RECOVERY trial publication on June 16, 2020, and to identify discrepancies in care.},
pages = {e220-e234},
volume = {4},
issue = {4},
journal = {The Lancet Digital Health},
publisher = {Elsevier},
url = {http://dx.doi.org/10.1016/S2589-7500(22)00018-8},
}
